Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
Top Cited Papers
- 1 October 2016
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 2 (10), 1346-1353
- https://doi.org/10.1001/jamaoncol.2016.1051
Abstract
Review from JAMA Oncology — Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors — A ReviewKeywords
This publication has 5 references indexed in Scilit:
- Faculty Opinions recommendation of Nivolumab in previously untreated melanoma without BRAF mutation.Published by H1 Connect ,2016
- Faculty Opinions recommendation of Pembrolizumab versus Ipilimumab in Advanced Melanoma.Published by H1 Connect ,2016
- Faculty Opinions recommendation of Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial.Published by H1 Connect ,2016
- Faculty Opinions recommendation of Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.Published by H1 Connect ,2016
- Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related ColitisCancer Biotherapy & Radiopharmaceuticals, 2009